Genaera News (NASDAQ:GENR)
| Latest Genaera News Headlines | | Date | Time | Source | | | 08/11/2008 | 8:00AM | PRNUS | Genaera Corporation Announces Second Quarter Financial Results
PLYMOUTH MEETING, Pa., Aug. 11 /PRNewswire-FirstCall/ -- Genaera Corporation (NASDAQ:GENR) today announced its financial results for the three- and six-month periods ended June 30, 2008. The net loss for the three-month period ended June 30, 2008 was $4.8 million, or $(0.27) per share basic and diluted, as compared... More...>> |
| 07/25/2008 | 8:00AM | PRNUS | Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
PLYMOUTH MEETING, Pa., July 25 /PRNewswire-FirstCall/ -- Genaera Corporation (NASDAQ:GENR) today announced interim Phase 1 safety and pharmacokinetic (PK) data and new preclinical data on trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity, during the CBI 4th Annual... More...>> |
| 07/14/2008 | 2:16PM | PRNUS | Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American So
PLYMOUTH MEETING, Pa., July 14 /PRNewswire-FirstCall/ -- Genaera Corporation (NASDAQ:GENR) announced today the presentation of new preclinical data on trodusquemine (MSI-1436), a novel inhibitor of PTP-1B and Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity, during the 10th Biennial FASEB... More...>> |
| 06/30/2008 | 10:57AM | PRNUS | Genaera Corporation Elects Paul K. Wotton to Board of Directors
PLYMOUTH MEETING, Pa., June 30 /PRNewswire-FirstCall/ -- Genaera Corporation (NASDAQ:GENR) today announced the election of Paul K. Wotton, Ph.D., to Genaera's Board of Directors, bringing the membership total to seven. Dr. Wotton is expected to serve for the remainder of the Board's existing term through the Company's... More...>> |
| 06/12/2008 | 4:44PM | PRNUS | Genaera Corporation to Present at BIO Business Forum
PLYMOUTH MEETING, Pa., June 12 /PRNewswire-FirstCall/ -- Genaera Corporation (NASDAQ:GENR) today announced that Jack Armstrong, President and Chief Executive Officer of Genaera, is scheduled to present at the BIO Business Forum. The presentation will provide an update on the Company's programs and will take place at... More...>> |
| 06/09/2008 | 8:00AM | PRNUS | Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diab
PLYMOUTH MEETING, Pa., June 9 /PRNewswire-FirstCall/ -- Genaera Corporation (NASDAQ:GENR) announced today a presentation by Genaera scientists of preclinical data on trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity, during the 68th Scientific Sessions of the American... More...>> |
| 06/02/2008 | 9:20AM | PRNUS | BeaconEquity.com Issues TraderNotes on Biotechnology Stocks: TPIM, RXII, VION, CUR, AMGN, GILD, BIIB, GENR
DALLAS, June 2 /PRNewswire/ -- BeaconEquity.com announces the availability of TraderNotes on stocks that are making news today.
Investors can view all of the daily trading notes for free by visiting: http://www.beaconequity.com/m
Today's TraderNotes include: TapImmune Inc. (OTC:TPIM) (BULLETIN BOARD: TPIM) , RXi Pharmaceuticals... More...>> |
| 05/30/2008 | 11:02AM | PRNUS | Genaera Corporation's 2008 Annual Stockholder Meeting Results
PLYMOUTH MEETING, Pa., May 30 /PRNewswire-FirstCall/ -- Genaera Corporation (NASDAQ:GENR) today announced the results of its Annual Meeting of Stockholders held on May 29, 2008. Proxies representing a majority of the shares voted at the Annual Meeting were cast in favor of the resolutions brought before the stockholders... More...>> |
| 05/09/2008 | 4:20PM | PRNUS | Genaera Corporation Announces First Quarter Financial Results
PLYMOUTH MEETING, Pa., May 9 /PRNewswire-FirstCall/ -- Genaera Corporation (NASDAQ:GENR) today announced its financial results for the quarter ended March 31, 2008. The net loss for the quarter ended March 31, 2008 was $4.3 million, or $(0.24) per basic and diluted share, as compared to a net loss of $4.2 million, or... More...>> |
| 05/09/2008 | 1:51PM | PRNUS | Xmark Comments on Genaera Cost-Saving Plan
RIDGEFIELD, Conn., May 9 /PRNewswire/ -- Xmark Opportunity Partners, LLC, the investment manager to Xmark Opportunity Fund, L.P., Xmark Opportunity Fund, Ltd. and Xmark JV Investment Partners, LLC, announced today that it fully supports the initiatives outlined in the press release issued by Genaera Corporation (NASDAQ:GENR... More...>> |
| 05/08/2008 | 8:00AM | PRNUS | Genaera Corporation Announces Initiatives to Conserve Resources to Continue Development Efforts
- Cash for Operations through Second Quarter 2009 -
PLYMOUTH MEETING, Pa., May 8 /PRNewswire-FirstCall/ -- Genaera Corporation (NASDAQ:GENR) today announced plans that will enable the Company to continue development efforts over the next 12 months for its trodusquemine (MSI-1436) type 2 diabetes and obesity program... More...>> |
| 04/07/2008 | 5:30PM | PRNUS | Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph
PLYMOUTH MEETING, Pa., April 7, 2008 /PRNewswire-FirstCall/ -- Genaera Corporation (NASDAQ:GENR) today announced, in compliance with NASDAQ Marketplace Rule 4350(b)(1)(B), that the audit report included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2007 contained an unqualified audit... More...>> |
| 03/31/2008 | 6:02PM | PRNUS | Genaera Corporation Announces 2007 Financial Results
PLYMOUTH MEETING, Pa., March 31 /PRNewswire-FirstCall/ -- Genaera Corporation (NASDAQ:GENR) today announced its financial results for the year and quarter ended December 31, 2007. The net loss for the year ended December 31, 2007 was $15.7 million, or $(0.90) per share basic and diluted, as compared to a net loss of... More...>> |
| 03/28/2008 | 8:00AM | PRNUS | Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
- Preclinical Data Indicates MSI-1436 Does Not Alter Rate of Dopamine Uptake -
PLYMOUTH MEETING, Pa., March 28 /PRNewswire-FirstCall/ -- Genaera Corporation (NASDAQ:GENR) announced that preclinical data was presented Thursday at the Chicago Chapter of the Society of Neuroscience by Mitchell F. Roitman, Ph.D., a Genaera... More...>> |
| 03/18/2008 | 4:37PM | PRNUS | Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
- Study to Assess MEDI-528 in Stable Asthma and Exercise-Induced Bronchoconstriction -
PLYMOUTH MEETING, Pa., March 18 /PRNewswire-FirstCall/ -- Genaera Corporation (NASDAQ:GENR) today reported that development partner, MedImmune, has initiated its fourth phase 2a clinical trial of MEDI-528, an anti-IL-9 monoclonal... More...>> |
| 02/07/2008 | 8:00AM | PRNUS | Genaera Corporation to Present at BIO CEO & Investor Conference
PLYMOUTH MEETING, Pa., Feb. 7 /PRNewswire-FirstCall/ -- Genaera Corporation (NASDAQ:GENR) today announced that Jack Armstrong, President and Chief Executive Officer of Genaera, is scheduled to present at the 10th Annual BIO CEO & Investor Conference. The presentation will provide an update on the Company's programs... More...>> |
| 01/24/2008 | 8:00AM | PRNUS | Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
New data supports recent IND and forms foundation for upcoming clinical programs
PLYMOUTH MEETING, Pa., Jan. 24 /PRNewswire-FirstCall/ -- Genaera Corporation (NASDAQ:GENR) announced today a poster presentation of preclinical data on trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2... More...>> |
| 01/23/2008 | 8:00AM | PRNUS | Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
- Second filing provides opportunity for additional indications and increased potential market -
PLYMOUTH MEETING, Pa., Jan. 23 /PRNewswire-FirstCall/ -- Genaera Corporation (NASDAQ:GENR) today announced that the investigational new drug (IND) application submitted to the US Food and Drug Administration (FDA) for trodusquemine... More...>> |
| 01/17/2008 | 10:29AM | PRNUS | Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
Study in Overweight and Obese Type 2 Diabetics to Assess Safety and Pharmacokinetics in addition to Specialized Secondary Endpoints
PLYMOUTH MEETING, Pa., Jan. 17 /PRNewswire-FirstCall/ -- Genaera Corporation (NASDAQ:GENR) today announced that dosing of subjects has begun in study MSI-1436C-103, the ascending single... More...>> |
| 12/12/2007 | 8:00AM | PRNUS | Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
PLYMOUTH MEETING, Pa., Dec. 12 /PRNewswire-FirstCall/ -- Genaera Corporation (NASDAQ:GENR) today announced that Jack Armstrong, President and Chief Executive Officer of Genaera, is scheduled to present at the 2007 RBC Capital Markets Healthcare Conference. The presentation is part of an RBC Capital Markets' panel discussion... More...>> |
|
|
|